270. Wiltink LM, Chen TY, Nout RA, et al. Health-related quality of life 14 years after preoperative

short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter

randomised trial. Eur J Cancer 2014;50(14):2390–2398.

271. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008;47(1):20–31.

272. Scott NA, Jeacock J, Kingston RD. Risk factors in patients presenting as an emergency with

colorectal cancer. Br J Surg 1995;82(3):321–323.

273. Wong SK, Jalaludin BB, Morgan MJ, et al. Tumor pathology and long-term survival in emergency

colorectal cancer. Dis Colon Rectum 2008;51(2):223–230.

274. McArdle CS, Hole DJ. Emergency presentation of colorectal cancer is associated with poor 5-year

survival. Br J Surg 2004;91(5):605–609.

275. Yeo HL, Lee SW. Colorectal emergencies: review and controversies in the management of large

bowel obstruction. J Gastrointest Surg 2013; 17(11):2007–2012.

276. Lopez-Kostner F, Hool GR, Lavery IC. Management and causes of acute large-bowel obstruction.

Surg Clin North Am 1997;77(6):1265–1290.

277. Batke M, Cappell MS. Adynamic ileus and acute colonic pseudo-obstruction. Med Clin North Am

2008;92(3):649–670, ix.

278. Dachman AH. What are the indications for use of water-soluble contrast agent enemas in colon

distension? AJR Am J Roentgenol 1996;166(4):988.

279. Maddu KK, Mittal P, Arepalli CD, et al. Colorectal emergencies and related complications: a

comprehensive imaging review–noninfectious and noninflammatory emergencies of colon. AJR

American J Roentgenol 2014;203(6):1217–1229.

280. Bass G, Fleming C, Conneely J, et al. Emergency first presentation of colorectal cancer predicts

significantly poorer outcomes: a review of 356 consecutive Irish patients. Dis Colon Rectum

2009;52(4):678–684.

281. Metcalfe MS, Norwood MG, Miller AS, et al. Unreasonable expectations in emergency colorectal

cancer surgery. Colorectal Dis 2005;7(3):275–278.

282. Tekkis PP, Kinsman R, Thompson MR, et al. The Association of Coloproctology of Great Britain and

Ireland study of large bowel obstruction caused by colorectal cancer. Ann Surg 2004;240(1):76–81.

283. Deans GT, Krukowski ZH, Irwin ST. Malignant obstruction of the left colon. Br J Surg

1994;81(9):1270–1276.

284. Watt AM, Faragher IG, Griffin TT, et al. Self-expanding metallic stents for relieving malignant

colorectal obstruction: a systematic review. Ann Surg 2007;246(1):24–30.

285. Cheung HY, Chung CC, Tsang WW, et al. Endolaparoscopic approach vs conventional open surgery

in the treatment of obstructing left-sided colon cancer: a randomized controlled trial. Arch Surg

2009;144(12):1127–1132.

286. Alcantara M, Serra-Aracil X, Falco J, et al. Prospective, controlled, randomized study of

intraoperative colonic lavage versus stent placement in obstructive left-sided colonic cancer. World

J Surg 2011;35(8):1904–1910.

287. Pirlet IA, Slim K, Kwiatkowski F, et al. Emergency preoperative stenting versus surgery for acute

left-sided malignant colonic obstruction: a multicenter randomized controlled trial. Surg Endosc

2011;25(6):1814–1821.

288. Ghazal AH, El-Shazly WG, Bessa SS, et al. Colonic endolumenal stenting devices and elective

surgery versus emergency subtotal/total colectomy in the management of malignant obstructed left

colon carcinoma. J Gastrointest Surg 2013;17(6):1123–1129.

289. van Hooft JE, Bemelman WA, Oldenburg B, et al. Colonic stenting versus emergency surgery for

acute left-sided malignant colonic obstruction: a multicentre randomised trial. Lancet Oncol

2011;12(4):344–352.

290. Sloothaak DA, van den Berg MW, Dijkgraaf MG, et al. Oncological outcome of malignant colonic

obstruction in the Dutch Stent-In 2 trial. Br J Surg 2014;101(13):1751–1757.

291. SCOTIA Study Group. Single-stage treatment for malignant left-sided colonic obstruction: a

prospective randomized clinical trial comparing subtotal colectomy with segmental resection

following intraoperative irrigation. Br J Surg 1995;82(12):1622–1627.

292. Sasaki K, Kazama S, Sunami E, et al. One-stage segmental colectomy and primary anastomosis after

intraoperative colonic irrigation and total colonoscopy for patients with obstruction due to left1825

sided colorectal cancer. Dis Colon Rectum 2012;55(1):72–78.

293. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis

Colon Rectum 2007;50(11):1783–1799.

294. Baca B, Beart RW Jr, Etzioni DA. Surveillance after colorectal cancer resection: a systematic

review. Dis Colon Rectum 2011;54(8):1036–1048.

295. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic

colorectal cancer. Cochrane Database Syst Rev 2007(1):Cd002200.

296. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal

cancer. Ann Surg 1979;189(4):496–502.

297. Siriwardena AK, Mason JM, Mullamitha S, et al. Management of colorectal cancer presenting with

synchronous liver metastases. Nat Rev Clin Oncol 2014;11(8):446–459.

298. Clancy C, Burke JP, Barry M, et al. A meta-analysis to determine the effect of primary tumor

resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg

Oncol 2014;21(12):3900–3908.

299. Cirocchi R, Trastulli S, Abraha I, et al. Non-resection versus resection for an asymptomatic primary

tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev

2012;8:Cd008997.

300. Hu CY, Bailey CE, You YN, et al. Time trend analysis of primary tumor resection for stage IV

colorectal cancer: less surgery, improved survival. JAMA Surg 2015;150(3):245–251.

301. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology – colon

cancer. Available at www.nccn.org. 2015.

302. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009: clinical

evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin

Oncol 2010;28(3):493–508.

303. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for

metastatic colorectal cancer. N Eng J Med 2014; 371(17):1609–1618.

304. Jones C, Taylor MA, McWilliams B. The role of cetuximab as first-line treatment of colorectal liver

metastases. HPB (Oxford) 2013;15(1):11–17.

305. Yaeger R, Cercek A, O’Reilly EM, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAFmutant metastatic colorectal cancer patients. Clin Cancer Res 2015;21(6):1313–1320.

306. Araujo R, Gonen M, Allen P, et al. Comparison between perioperative and postoperative

chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. Ann Surg

Oncol 2013;20(13):4312–4321.

307. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery

versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial

40983): a randomised controlled trial. Lancet 2008;371(9617):1007–1016.

308. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery

versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): longterm results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14(12):1208–1215.

309. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in

metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91(3):173–180.

310. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in

patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.

Lancet Oncol 2014; 15(6):601–611.

311. Ychou M, Rivoire M, Thezenas S, et al. A randomized phase II trial of three intensified

chemotherapy regimens in first-line treatment of colorectal cancer patients with initially

unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol

2013;20(13):4289–4297.

312. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and

without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol

2009;27:663–671.

313. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for

metastatic colorectal cancer. N Eng J Med 2009;360:1408–1417.

314. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional,

1826

bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from

the BICC-C Study. J Clin Oncol 2007;25(30):4779–4786.

315. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based

chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J

Clin Oncol 2008;26:2013–2019.

316. Cercek A, Saltz L. Factors dictating outcomes in patients with colorectal cancer and peritoneal

carcinomatosis: selection, resection, or convection? J Clin Oncol 2012;30(3):226–228.

317. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with

systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group phase III trials

N9741 and N9841. J Clin Oncol 2012;30(3):263–267.

318. Hompes D, D’Hoore A, Wolthuis A, et al. The use of oxaliplatin or mitomycin C in HIPEC treatment

for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol

2014;109(6):527–532.

319. Chua TC, Esquivel J, Pelz JO, et al. Summary of current therapeutic options for peritoneal

metastases from colorectal cancer. J Surg Oncol 2013;107(6):566–573.

320. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and

hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with

peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426–2432.

321. Cao C, Yan TD, Black D, et al. A systematic review and meta-analysis of cytoreductive surgery with

perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann

Surg Oncol 2009;16(8):2152–2165.

322. Pelz JO, Stojadinovic A, Nissan A, et al. Evaluation of a peritoneal surface disease severity score in

patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 2009;99(1):9–15.